J&J Vaccine Significantly Less Effective Against CCP Virus Variants, Study Suggests

The Johnson & Johnson vaccine against COVID-19 is significantly less effective against variants compared to the two other COVID-19 vaccines approved for use in the United States, a pre-print study by scientists from the New York University School of Medicine suggests. According to the paper’s summary, the antibodies elicited by the Pfizer-BioNTech and Moderna vaccines “showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants.” In contrast, the antibodies generated in response to the Johnson & Johnson vaccine had “significantly decreased neutralization.” “The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following [the Johnson & Johnson vaccine] to increase protection against the variants,” the study states. The Epoch Times contacted Johnson & Johnson for comment. The study has not been peer-reviewed and should not be used to guide health behavior or viewed as conclusive. It …

Related Post

This website uses cookies.